Activating Neuroplasticity to ENHANCE the Perception Box Expanding Effects of Psilocybin (the ENHANCE Study)
Sponsor: Tiny Blue Dot Foundation
Principal Investigator: Charles Raison, MD
Purpose: The purpose of the study is to explore whether vagus nerve stimulation (VNS) may enhance the wellbeing-related effects of psilocybin. Psilocybin is a drug with temporary psychedelic effects that is not approved by the US Food and Drug Administration (FDA), but the FDA has allowed for the use of psilocybin in research. The VNS used in this study is a non-invasive, at home procedure that applies gentle electrical stimulation to the ear.
Study Population: English-speaking adults, 18-70 years old with reduced wellbeing, who meet other eligibility criteria as determined in the pre-screening process.
Interested? If interested in participating, you can find out more about the study here and/or complete our online survey to see if you are eligible, in which case you may be contacted by the study team.
Role of Experience, Conscious Awareness, and Plasticity in Psilocybin’s Behavioral Effects – Follow-Up Study (the RECAP2 Study)
Principal Investigator: Charles Raison, MD
Purpose: The purpose of this study is to investigate the role that inducing neuroplasticity (the brain’s ability to adapt and change) plays in the behavioral effects of psilocybin in people who have experienced a mild decline in emotional wellbeing. Psilocybin is a drug with temporary psychedelic effects that is not approved by the US Food and Drug Administration (FDA), but the FDA has allowed for the use of psilocybin in research.
Study Population: English-speaking adults, 18-70 years old with reduced wellbeing, who meet other eligibility criteria as determined in the pre-screening process.
Interested? If interested in participating, you can find out more about the study here. Please check back soon for an eligibility survey link that will be activated when recruitment begins for this study.
Consciousness and Psilocybin Effects on Well-Being (the CoPE Study): Pilot Phase
The Raison Lab at UW-Madison is currently recruiting for a study, sponsored by the Tiny Blue Dot Foundation, titled “Consciousness and Psilocybin Effects on Well-Being (The CoPE Study): Pilot Phase.”
The goal of this study is to identify a method to deliver psilocybin intravenously during sleep. Psilocybin is a drug with temporary psychedelic effects that is not yet approved by the US Food and Drug Administration (FDA), but the FDA has allowed for the use of psilocybin in research.
The target study population is healthy adults, 18-45 years old, not currently taking an antidepressant, preferably who have prior experience with psychedelics.
If interested in participating, you can find out more about the study on clinicaltrials.gov (ID NCT05592379) and/or complete our REDCap survey to see if you are eligible and be contacted by the study team.